Diabetic kidney disease
Conditions
Interventions
Drug administration group (Dagliflozin/Calcagliflozin):None
Sponsors
Affiliated Hospital of Jiangnan University
Eligibility
Sex/Gender
Male
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Age >18 years; met diagnostic criteria for type 2 diabetes; met diagnostic criteria for diabetic nephropathy; urinary albumin creatinine ratio =30 mg/g or 3 mg/mmol; stable treatment dose of ACEIs/ARBs for at least 2 months or no use for 4 weeks; no other medication affecting urinary protein for 4 weeks (see Appendix 1 for details); female subjects were menopausal, or using surgical contraception, or using contraceptives within 3 months prior to screening and during the study period.
Exclusion criteria
Exclusion criteria: New York Heart Assignment (NYHA) class III-IV; systolic/diastolic blood pressure >180/110 mmHg; heart valve disease, aortic disease; renal artery stenosis; persistent erythrocyturia and/or urinary tract infection; creatinine clearance <45 mL/min; tumor; autoimmune disease; abnormal liver function; chronic wasting disease; pregnant and lactating women; presence of alcohol or drug abuse; unwillingness to comply with trial arrangements or automatic withdrawal.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Urinary microalbumin creatinine ratio; | — |
Secondary
| Measure | Time frame |
|---|---|
| Fasting blood glucose;2h postprandial glucose;Glycated hemoglobin; | — |
Countries
China
Contacts
Public ContactJinfang Song
Affiliated Hospital of Jiangnan University
Outcome results
None listed